<DOC>
	<DOCNO>NCT01364662</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , dose-ranging , efficacy safety study child impulsive aggression comorbid Attention-Deficit/Hyperactivity Disorder ( ADHD ) . The target subject healthy male female child age 6 12 year , inclusive , diagnosis ADHD . A total 120 subject randomize across approximately 30 US center one four treatment group .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety SPN-810 Adjunctive Therapy Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>1 . Healthy pediatric male female subject , age 6 12 year . 2 . Diagnostic Statistical Manual Mental Disorders IV Text Revision ( DSMIVTR ) diagnosis ADHD . 3 . RMOAS score &gt; =24 screen RMOAS score &gt; =20 randomization 4 . IQ great 71 . 5 . Weight &gt; =20kg 6. current treatment psychostimulant ( 1 month prior screen )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Impulsive Aggression</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
</DOC>